Abstract
CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2% and 3% complete response; median survival was 4 months with 2 patients alive 18 months from starting salvages chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Cisplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Resistance
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Leukopenia / chemically induced
-
Lomustine / administration & dosage
-
Lung Neoplasms / drug therapy*
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Remission Induction
-
Salvage Therapy*
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Etoposide
-
Lomustine
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Methotrexate